Tobacco Treatment as Augmentation for Cognitive Processing Therapy for PTSD
6 september 2016 uppdaterad av: VA Office of Research and Development
Tobacco Treatment as Augmentation to Cognitive Processing Therapy for PTSD
The purpose of this study is to examine whether tobacco affects recovery from PTSD.
There are 3 goals of the study; (1) to test if quitting tobacco prior to PTSD treatment affects treatment success, (2) to test how PTSD symptoms change in those who have quit tobacco compared to those who continue to use and (3) to explore how tobacco use and tobacco withdrawal symptoms change during PTSD treatment.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The proposed research aims to examine the effect of tobacco on PTSD symptoms and PTSD recovery as well as the effect of PTSD recovery on tobacco use.
This study has 3 aims: (1) to evaluate whether tobacco use interferes with recovery from PTSD during empirically based, trauma focused PTSD treatment.
(2) To gather preliminary data about whether tobacco use alleviates PTSD symptoms among continued tobacco users vs. recent quitters.
(3) To explore the impact of recovery from PTSD treatment on tobacco use quantity and frequency, tobacco withdrawal symptoms, and craving for tobacco.
To test these aims, the investigators propose a randomized two group design where 75 participants are assigned to receive either tobacco treatment (Contingency Management plus Cognitive Behavioral Therapy) or control treatment (Health Education) before completing Cognitive Processing Therapy (CPT) for PTSD.
Study outcome variables will be PTSD symptom severity following CPT, PTSD symptom severity during tobacco cessation treatment, and tobacco use and tobacco withdrawal during CPT.
Studietyp
Interventionell
Inskrivning (Faktisk)
19
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02130
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- current tobacco use (a urine cotinine level 200ng/ml),
- motivation to quit (measured by the 7 on the Biener Contemplation ladder)
- and a current diagnosis of PTSD [as diagnosed by the Clinician Administered PTSD Scale for DSM-5]
Exclusion Criteria:
- Exclusion criteria will include current participation in another research study, history of bipolar I disorder,
- schizophreniform disorders except for psychosis NOS due to presence of trauma-related sensory hallucinations,
- cognitive impairment (<25 of the Mini Mental State Exam),
- current suicidality/homicidality requiring clinical intervention or a suicide attempt in the past year,
- inability to provide reliable study data (e.g., provide an adulterated urine sample,
- provide misinformation to study staff including stating differing information to two or more staff members,
- attempt to misrepresent self in order to avoid being excluded from the study,
- inability to answer study questions which are used to determine eligibility),
- current non-tobacco substance use disorder (abuse or dependence or a positive drug screen; participants who have been abstinent for greater than 3 months will be allowed to participate),
- participation within the past 6 months in trauma-focused therapy (e.g., Prolonged Exposure, Cognitive Processing Therapy),
- current use of tobacco cessation pharmacotherapy (i.e., nicotine replacement therapy or varenicline),
- current use of benzodiazepines
- serious or uncontrolled medical condition precluding unaided tobacco cessation attempts,
- pregnancy,
- a recent change in psychiatric medications (change occurred <2 months prior to entering the study),
- current participation in another research study.
- In addition, participants must agree to keep psychiatric medication doses stable for the duration of the study (except for dose adjustments for changes in medication blood levels due to tobacco cessation), unless there is a concern for participant safety.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: tobacco treatment
participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
|
participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
|
|
Sham Comparator: health education treatment
Participants will be provided education on a variety of health topics and will set health goals around each topic
|
Participants will be provided education on a variety of health topics and will set health goals around each topic
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Clinician Administered PTSD Scale
Tidsram: end of 6 week PTSD treatment
|
posttraumatic stress disorder clinician rated symptom ratings; scores range from 0-80 (with higher scores indicating greater PTSD severity)
|
end of 6 week PTSD treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percent Abstinent From Tobacco Use
Tidsram: end of treatment
|
biochemically confirmed abstinence from tobacco using self-report, cotinine, and CO breath samples
|
end of treatment
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Utredare
- Huvudutredare: Sandra Japuntich, PhD, VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 december 2014
Primärt slutförande (Faktisk)
1 januari 2016
Avslutad studie (Faktisk)
1 januari 2016
Studieregistreringsdatum
Först inskickad
26 september 2013
Först inskickad som uppfyllde QC-kriterierna
9 december 2013
Första postat (Uppskatta)
16 december 2013
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
27 oktober 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
6 september 2016
Senast verifierad
1 september 2016
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- NURA-018-13S
- 1IK2CX000918-01A1 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .